The panel publishes 24 amounts, led by Calcium 150 mg, Omega-3 Fatty Acids (from fish oil) 235 mg.
Rebuilt from public sources on July 22, 2026 · evidence availability is not a safety or effectiveness verdict.
The panel gives a per-ingredient amount rather than hiding quantities inside a proprietary blend, so each one can be compared to published research.
Specific fact confirmed
USPTO lists Bayer HealthCare LLC (LIMITED LIABILITY COMPANY) in DELAWARE, USA for the exact brand wordmark. This identifies the USPTO mark owner or applicant; it does not by itself prove who manufactures or sel…
We did the comparison: the listing claims 235 mg of omega-3 fatty acids (from fish oil), and the listing-image panel shows 235 mg omega-3 fatty acids (from fish oil) one softgel. Those amounts agree. This is internal consistency, not independent lab testing.
| Panel row | Amount | %DV | What to notice |
|---|---|---|---|
| Omega-3 Fatty Acids (from fish oil) | 235 mg | — | |
| Total Fat | 0.5 g | — | |
| DHA (docosahexaenoic acid) | 200 mg | — | |
| Calcium | 150 mg | — | |
| Vitamin C | 85 mg | — |
FDA rules (21 CFR 101.36) require the amount of each dietary ingredient per serving unless hidden in a declared “proprietary blend” (legal, but a transparency yellow flag). A label stating no amount at all is non-compliant — a checkable red flag. This panel states amounts; any remaining comparison concerns the front-label framing.
vision:google/gemini-flash-1.5 Amounts are shown as declared panel data, not independently lab-tested contents.
The panel declares 235 mg EPA + DHA per serving, below one studied 300–1800 mg/day context. The fish-oil concentrate total is not substituted for EPA + DHA.
100 Bayer Boulevard, Whippany, NEW JERSEY 07981, UNITED STATES
Filed address
100 Bayer Boulevard, Whippany, NEW JERSEY 07981, UNITED STATES
This is the USPTO owner of the brand wordmark. It tells a shopper who is behind the brand, but does not by itself identify the manufacturer or prove where this product was made.
These links provide the public research context used alongside the captured panel. They do not establish safety, effectiveness, or product quality.
The summary stops at product-specific facts. The full report preserves every source, calculation, limitation, and unresolved check for review or sharing.
Confirmed evidence
These checks found support in the public record. They confirm specific facts, not the product as a whole.
The panel gives a per-ingredient amount rather than hiding quantities inside a proprietary blend, so each one can be compared to published research.
USPTO lists Bayer HealthCare LLC (LIMITED LIABILITY COMPANY) in DELAWARE, USA for the exact brand wordmark. This identifies the USPTO mark owner or applicant; it does not by itself prove who manufactures or sells this product.
Documented concerns
These are documented contradictions or claims that need more evidence. They are separate from missing data.
No contradictions or product-specific cautions were found at this check depth.
Unresolved public record
We looked for these signals but could not settle them from public sources. A gap is not a strike.
Marketplace rating not shown★ — rating count unavailable. No exact-listing count history was available, so no review-pattern claim is made.
The panel declares 235 mg EPA + DHA per serving (One softgel). One randomized dose-response trial used 300–1,800 mg/day; omega-3 studies vary widely. This is research context, not a recommendation or safety verdict.
We read the full Supplement Facts panel from the listing-image panel (below), but the label doesn’t state a serving weight, so the arithmetic can’t run. A gap in the label’s information, not evidence of a problem.
Published sources describe how omega-3, magnesium, zinc have been studied. This is ingredient context only; the record does not establish that this product delivers the studied dose or outcome. Sources: NIH ODS — Omega-3 Fatty Acids fact sheet, PubMed dose-response trial.
The NIH Dietary Supplement Label Database has no matching label yet. Ingestion lags the market — recorded as a gap, not a strike.
Check digit passes; no third-party database record found yet. Coverage gaps are common — not a strike.
What to ask and check
Ask the brand or seller
Answered by the panel: the 0.235 g listing number equals Thiamin (B1) 1.4 mg + Omega-3 Fatty Acids (from fish oil) 235 mg. What lot-specific document confirms those declared amounts?
The panel resolves what the headline number includes. The remaining question is whether the product in hand matches those declared amounts; ask for a lot-specific certificate of analysis.
Is this label filed with NIH’s Dietary Supplement Label Database (DSLD)?
Filing is voluntary, so absence proves nothing — but a filed label puts the full ingredient table on public record where anyone can read it.
Most brands and sellers publish a contact route. A clear answer adds evidence to the record; no answer leaves the question open.
Check for yourself — no one’s permission needed
Compare the panel on the bottle in your hand to the one shown in this record.
Ours was read from listing photos and can contain reading errors. The physical label is the source of truth — if they disagree, tell us and we’ll correct the record.
Scan the barcode on the package and confirm it reads 016500563907.
A mismatch between the barcode on the box and the one on the listing is worth pausing over — it can indicate a different variant, a repack, or a counterfeit.
Check the lot number and expiry on the bottle against any COA you’re given.
A certificate that doesn’t name your lot doesn’t describe what you’re holding.
These are the open questions on this specific record — not a warning about the product, and not a suggestion to buy or avoid it. Getting them answered is how you decide for yourself.
Record built July 22, 2026. Sources: source listing observed at check time · USPTO Trademark Search · Keepa exact-listing history · NIH / published research · certification and regulator records where available. LookCloser publishes evidence and gaps; it does not advise for or against any supplement. Evidence-based corrections welcome.